Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors

Tanaka, Hidekazu; Tatsumi, Kazuhiro; Matsuzoe, Hiroki; Soga, Fumitaka; Matsumoto, Kensuke; Hirata, Ken‐ichi

doi:10.1007/s10554-020-02122-x

Cited by 6 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 In a study enrolling patients with type 2 diabetes and non-ischemic dilated cardiomyopathy, pharmacological ketosis, that is, treatment with SGLT2 inhibitors, significantly reduced the incidence of NOAF. 23 Consistently, our study suggests that positive urine ketone was associated with reduced risk of NOAF.…”

Section: Discussionsupporting

confidence: 84%

“…More importantly, regardless of the method used to increase cardiac ketone delivery, a generally favorable effect was observed in CVD settings 14 . In a study enrolling patients with type 2 diabetes and non‐ischemic dilated cardiomyopathy, pharmacological ketosis, that is, treatment with SGLT2 inhibitors, significantly reduced the incidence of NOAF 23 . Consistently, our study suggests that positive urine ketone was associated with reduced risk of NOAF.…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

The association between urine ketone and new‐onset atrial fibrillation in critically ill patients

Zhang,

Tse

et al. 2023

Pacing Clinical Electrophis

View full text Add to dashboard Cite

BACKGROUND AND AIMSNew‐onset atrial fibrillation (NOAF) is a common manifestation in critically ill patients. There is a paucity of evidence indicating a relationship between urinary ketones and NOAF.METHODSCritically ill patients with urinary ketone measurements from the Medical Information Mart for Intensive Care (MIMIC‐IV) database were included. The primary outcome was NOAF Propensity score matching was performed following by multivariable logistic regression.RESULTSA total of 24,688 patients with available data of urine ketone were included in this study. The urine ketone of 4014 patients was tested positive. The average age of the included participants was 63.8 years old, and 54.5% of them were male. Result of the fully‐adjusted binary logistic regression model showed that patients with positive urinary ketone was associated with a significantly lower risk of NOAF (Odds ratio, 0.79, 95% CI 0.7–0.9), compared with those with negative urinary ketone. In the subgroup analysis according to diabetic status, compared with nondiabetics, patients with diabetes had lower risk of NOAF (p‐values for interaction < 0.05). Results of other subgroup analyses according to gender, age, infection, myocardial infarction, and congestive heart failure were consistent with the primary analysis.CONCLUSIONSPositive urinary ketone body may be associated with reduced risk of NOAF in critically ill patients during intensive care unit hospitalization. Further studies are needed to clarify the underlying mechanisms.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 75%

The association between urine ketone and new‐onset atrial fibrillation in critically ill patients

Zhang,

Tse

et al. 2023

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

“…Therefore, SGLT2i may confer a specific AF or atrial flutter-reduction benefit not only in T2DM patients but also in high risk populations [117,118]. The treatment with SGLT2i also significantly reduced the development of new-onset AF in the T2DM patients who had non-ischemic dilated cardiomyopathy [119].…”

Section: Antiarrhythmic Efficacy Of Sglt2 Inhibitorsmentioning

confidence: 98%

Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress

Andelová

Bacova

Sýkora

et al. 2022

IJMS

View full text Add to dashboard Cite

The prevention of cardiac life-threatening ventricular fibrillation and stroke-provoking atrial fibrillation remains a serious global clinical issue, with ongoing need for novel approaches. Numerous experimental and clinical studies suggest that oxidative stress and inflammation are deleterious to cardiovascular health, and can increase heart susceptibility to arrhythmias. It is quite interesting, however, that various cardio-protective compounds with antiarrhythmic properties are potent anti-oxidative and anti-inflammatory agents. These most likely target the pro-arrhythmia primary mechanisms. This review and literature-based analysis presents a realistic view of antiarrhythmic efficacy and the molecular mechanisms of current pharmaceuticals in clinical use. These include the sodium‑glucose cotransporter-2 inhibitors used in diabetes treatment, statins in dyslipidemia and naturally protective omega-3 fatty acids. This approach supports the hypothesis that prevention or attenuation of oxidative and inflammatory stress can abolish pro-arrhythmic factors and the development of an arrhythmia substrate. This could prove a powerful tool of reducing cardiac arrhythmia burden.

show abstract

“…In a study with HF patients with non-ischemic etiology and type 2 DM, SGLT2is reduced the risk of developing new-onset AF [ 72 ]. A total of 210 HF patients with non-ischemic and sinus rhythm and reduced left ventricular ejection fraction of 31.0 ± 8.2% were enrolled; 60 of them also suffered from DM.…”

Section: Effect Of Sglt2 Inhibition In Atrial Fibrillation: Clinical ...mentioning

confidence: 99%

“…Of the 60 HF and DM patients, those treated with SGLT2is (20 with dapagliflozin, 7 with empagliflozin and 5 with canagliflozin) experienced fewer occurrences of the development of new-onset AF compared to those not receiving SGLLT2is (log-rank p = 0.040). Despite the limited number of patients, it was shown that DM is related to new-onset AF manifestation and SGLT2i administration can significantly reduce AF development in DM patients [ 72 ].…”

Section: Effect Of Sglt2 Inhibition In Atrial Fibrillation: Clinical ...mentioning

confidence: 99%

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation

Karamichalakis

Kolovos

Paraskevaidis

et al. 2022

JCDD

View full text Add to dashboard Cite

Atrial arrhythmias are common in patients with diabetes mellitus (DM), and despite recent advances in pharmaceutical and invasive treatments, atrial fibrillation (AF) and atrial flutter (AFl) are still associated with substantial mortality and morbidity. Clinical trial data imply a protective effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on the occurrence of AF and AFl. This review summarizes the state of knowledge regarding DM-mediated mechanisms responsible for AF genesis and recurrence but also discusses the recent data from experimental studies, published trials and metanalyses.

show abstract

Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors

Cited by 6 publications

References 34 publications

The association between urine ketone and new‐onset atrial fibrillation in critically ill patients

The association between urine ketone and new‐onset atrial fibrillation in critically ill patients

Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation

Contact Info

Product

Resources

About